|
1
|
Petersen PE: Strengthening the prevention
of oral cancer: The WHO perspective. Community Dent Oral Epidemiol.
33:397–399. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Camargo Cancela M, Voti L, Guerra-Yi M,
Chapuis F, Mazuir M and Curado MP: Oral cavity cancer in developed
and in developing countries: Population-based incidence. Head Neck.
32:357–367. 2010.PubMed/NCBI
|
|
3
|
2009 Statistics of Causes of Death.
Ministry of Health and Welfare. Taipei, Taiwan: 2010.
|
|
4
|
Chabner BA and Roberts TG Jr: Timeline:
Chemotherapy and the war on cancer. Nat Rev Cancer. 5:65–72. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Andreadis C, Vahtsevanos K, Sidiras T,
Thomaidis I, Antoniadis K and Mouratidou D: 5-Fluorouracil and
cisplatin in the treatment of advanced oral cancer. Oral Oncol.
39:380–385. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ramos P and Bentires-Alj M:
Mechanism-based cancer therapy: Resistance to therapy, therapy for
resistance. Oncogene. 34:3617–3626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dean M, Rzhetsky A and Allikmets R: The
human ATP-binding cassette (ABC) transporter superfamily. Genome
Res. 11:1156–1166. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stavrovskaya AA and Stromskaya TP:
Transport proteins of the ABC family and multidrug resistance of
tumor cells. Biochemistry (Mosc). 73:592–604. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Surowiak P, Materna V, Kaplenko I,
Spaczynski M, Dolinska-Krajewska B, Gebarowska E, Dietel M, Zabel M
and Lage H: ABCC2 (MRP2, cMOAT) can be localized in the nuclear
membrane of ovarian carcinomas and correlates with resistance to
cisplatin and clinical outcome. Clin Cancer Res. 12:7149–7158.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hall MD, Okabe M, Shen DW, Liang XJ and
Gottesman MM: The role of cellular accumulation in determining
sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol
Toxicol. 48:495–535. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamasaki M, Makino T, Masuzawa T, Kurokawa
Y, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Matsuura N, Mori
M and Doki Y: Role of multidrug resistance protein 2 (MRP2) in
chemoresistance and clinical outcome in oesophageal squamous cell
carcinoma. Br J Cancer. 104:707–713. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kool M, de Haas M, Scheffer GL, Scheper
RJ, van Eijk MJ, Juijn JA, Baas F and Borst P: Analysis of
expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the
multidrug resistance-associated protein gene (MRP1), in human
cancer cell lines. Cancer Res. 57:3537–3547. 1997.PubMed/NCBI
|
|
14
|
Guminski AD, Balleine RL, Chiew YE,
Webster LR, Tapner M, Farrell GC, Harnett PR and Defazio A: MRP2
(ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian
carcinoma. Gynecol Oncol. 100:239–246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taniguchi K, Wada M, Kohno K, Nakamura T,
Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S and Kuwano
M: A human canalicular multispecific organic anion transporter
(cMOAT) gene is overexpressed in cisplatin-resistant human cancer
cell lines with decreased drug accumulation. Cancer Res.
56:4124–4129. 1996.PubMed/NCBI
|
|
16
|
Materna V, Stege A, Surowiak P, Priebsch A
and Lage H: RNA interference-triggered reversal of ABCC2-dependent
cisplatin resistance in human cancer cells. Biochem Biophys Res
Commun. 348:153–157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie SM, Fang WY, Liu Z, Wang SX, Li X, Liu
TF, Xie WB and Yao KT: Lentivirus-mediated RNAi silencing targeting
ABCC2 increasing the sensitivity of a human nasopharyngeal
carcinoma cell line against cisplatin. J Transl Med. 6:552008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Minegaki T, Takara K, Hamaguchi R,
Tsujimoto M and Nishiguchi K: Factors affecting the sensitivity of
human-derived esophageal carcinoma cell lines to 5-fluorouracil and
cisplatin. Oncol Lett. 5:427–434. 2013.PubMed/NCBI
|
|
19
|
Agulnik M: New approaches to EGFR
inhibition for locally advanced or metastatic squamous cell
carcinoma of the head and neck (SCCHN). Med Oncol. 29:2481–2491.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mendelsohn J and Baselga J: Epidermal
growth factor receptor targeting in cancer. Semin Oncol.
33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chong CR and Jänne PA: The quest to
overcome resistance to EGFR-targeted therapies in cancer. Nat Med.
19:1389–1400. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang M, Zhang X, Bai CX, Song XR, Chen J,
Gao L, Hu J, Hong QY, West MJ and Wei MQ: Silencing the epidermal
growth factor receptor gene with RNAi may be developed as a
potential therapy for non small cell lung cancer. Genet Vaccines
Ther. 3:52005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wong DY, Chang KW, Chen CF and Chang RC:
Characterization of two new cell lines derived from oral cavity
human squamous cell carcinomas - OC1 and OC2. J Oral Maxillofac
Surg. 48:385–390. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lai YH, He RY, Chou JL, Chan MW, Li YF and
Tai CK: Promoter hypermethylation and silencing of tissue factor
pathway inhibitor-2 in oral squamous cell carcinoma. J Transl Med.
12:2372014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shichinohe T, Bochner BH, Mizutani K,
Nishida M, Hegerich-Gilliam S, Naldini L and Kasahara N:
Development of lentiviral vectors for antiangiogenic gene delivery.
Cancer Gene Ther. 8:879–889. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shintani S, Li C, Mihara M, Nakashiro K
and Hamakawa H: Gefitinib (‘Iressa’), an epidermal growth factor
receptor tyrosine kinase inhibitor, mediates the inhibition of
lymph node metastasis in oral cancer cells. Cancer Lett.
201:149–155. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takaoka S, Iwase M, Uchida M, Yoshiba S,
Kondo G, Watanabe H, Ohashi M, Nagumo M and Shintani S: Effect of
combining epidermal growth factor receptor inhibitors and cisplatin
on proliferation and apoptosis of oral squamous cell carcinoma
cells. Int J Oncol. 30:1469–1476. 2007.PubMed/NCBI
|
|
28
|
Shintani S, Li C, Mihara M, Terakado N,
Yano J, Nakashiro K and Hamakawa H: Enhancement of tumor
radioresponse by combined treatment with gefitinib (Iressa,
ZD1839), an epidermal growth factor receptor tyrosine kinase
inhibitor, is accompanied by inhibition of DNA damage repair and
cell growth in oral cancer. Int J Cancer. 107:1030–1037. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shintani S, Li C, Mihara M, Yano J,
Terakado N, Nakashiro K and Hamakawa H: Gefitinib (‘Iressa’,
ZD1839), an epidermal growth factor receptor tyrosine kinase
inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral
squamous cell carcinoma cell lines. Oral Oncol. 40:43–51. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee EJ, Whang JH, Jeon NK and Kim J: The
epidermal growth factor receptor tyrosine kinase inhibitor ZD1839
(Iressa) suppresses proliferation and invasion of human oral
squamous carcinoma cells via p53 independent and MMP, uPAR
dependent mechanism. Ann N Y Acad Sci. 1095:113–128. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dai W, Li Y, Zhou Q, Xu Z, Sun C, Tan X
and Lu L: Cetuximab inhibits oral squamous cell carcinoma invasion
and metastasis via degradation of epidermal growth factor receptor.
J Oral Pathol Med. 43:250–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qian M, Qian D, Jing H, Li Y, Ma C and
Zhou Y: Combined cetuximab and celecoxib treatment exhibits a
synergistic anticancer effect on human oral squamous cell carcinoma
in vitro and in vivo. Oncol Rep. 32:1681–1688.
2014.PubMed/NCBI
|
|
33
|
Ohnishi Y, Minamino Y, Kakudo K and Nozaki
M: Resistance of oral squamous cell carcinoma cells to cetuximab is
associated with EGFR insensitivity and enhanced stem cell-like
potency. Oncol Rep. 32:780–786. 2014.PubMed/NCBI
|
|
34
|
Zhou SF, Wang LL, Di YM, Xue CC, Duan W,
Li CG and Li Y: Substrates and inhibitors of human multidrug
resistance associated proteins and the implications in drug
development. Curr Med Chem. 15:1981–2039. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Falasca M and Linton KJ: Investigational
ABC transporter inhibitors. Expert Opin Investig Drugs. 21:657–666.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu M, Ocana A and Tannock IF: Reversal of
ATP-binding cassette drug transporter activity to modulate
chemoresistance: Why has it failed to provide clinical benefit?
Cancer Metastasis Rev. 32:211–227. 2013. View Article : Google Scholar : PubMed/NCBI
|
